Daniel Haraf
University of Chicago
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Daniel Haraf as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 06:51 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT03423264 · PROGRESS Trial - Prophylactic Gabapentin for Relief of Symptoms and Improved SwallowingUniversity of Chicago · withdrawn · Oropharyngeal Cancer, HPV-Related Squamous Cell Carcinoma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 06:51 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- CORE--BIOSTATISTICS, DATA MANAGEMENT AND CLINICALP50DE011921 · NIDCR · UNIVERSITY OF CHICAGO · fiscal years 1996 to 2001 · $103,677 awarded in 2001Same name and institution; not confirmed by an ID
- CORE--CLINICAL TRIAL PROTOCOL REVIEW AND MONITORING SYSTEMP30CA014599 · NCI · UNIVERSITY OF CHICAGO · fiscal years 1996 to 2000 · $289,716 awarded in 2000Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 06:51 UTC. The ranking covers the 200 most relevant of 71 PubMed records, and a shared surname and initials can bring in a namesake. All 71 on PubMed
- Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer.J Clin Oncol · 2014422 citationsRCR 14.0
- 274 citationsRCR 8.0
- Quality of life and performance in advanced head and neck cancer patients on concomitant chemoradiotherapy: a prospective examination.J Clin Oncol · 1999188 citationsRCR 6.5
- Concomitant chemoradiotherapy as primary therapy for locoregionally advanced head and neck cancer.J Clin Oncol · 2000170 citationsRCR 5.6
- OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer.Ann Oncol · 2019169 citationsRCR 7.8
- Concomitant infusional paclitaxel and fluorouracil, oral hydroxyurea, and hyperfractionated radiation for locally advanced squamous head and neck cancer.J Clin Oncol · 2001133 citationsRCR 4.3
- Phase I study of docetaxel with concomitant thoracic radiation therapy.J Clin Oncol · 1998133 citationsRCR 4.1
- Re-irradiation with concomitant chemotherapy of unresectable recurrent head and neck cancer: a potentially curable disease.Ann Oncol · 1996119 citationsRCR 4.1
- Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer.J Clin Oncol · 2008115 citationsRCR 2.8
- Favorable long-term survival following induction chemotherapy with cisplatin, fluorouracil, and leucovorin and concomitant chemoradiotherapy for locally advanced head and neck cancer.J Natl Cancer Inst · 1992103 citationsRCR 4.3